The biotech sector can offer unique opportunities and strong returns to investors willing to stomach the volatility heightened by the current economic environment. Shares of Verve Therapeutics (VERV) traded up 22% last Tuesday after the company’s recent announcement that it dosed its first human patient with an investigational in vivo base-editing medicine, VERVE-101, as a [...] The post Shares of Verve Therapeutics Up 84% in Past Month; Get Exposure With ARKG appeared first on ETF Trends .